Clinical Trial Update: Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003) [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing Opevesostat (MK-5684) to an alternative novel hormonal agent in metastatic prostate cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Opevesostat (MK-5684)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Prostate Cancer Metastatic | Phase 3 | Status: RECRUITING